NewswireToday - /newswire/ -
Beijing, China, 2010/06/24 - Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment has demonstrated in the best case that it could reconstruct a patient's natural insulin production and even reverse later complications in a clinical study.
The clinical study, jointly conducted by scientists and doctors of the Cellonis clinical research team, aims to help patients be free from insulin and oral drugs, by reconstructing their natural insulin production damaged by either autoimmune disorder (T1DM) or hyperglycemia, and also improve insulin sensitivity (T2DM). Using injections of autologous stem cells from the patient's bone marrow, the research team believes that this therapy could help patients return to a life without annoying everyday injections and drugs.
"Most of the patients in our clinical study are now taking less synthetic insulin or oral drugs for BG control," says Dr. Chase Dai, Chief Medical Officer at Cellonis. “We appear to have restored the biological insulin producing function of the body. We are excited to see that some patients have been treatment-free for five months now, and we believe the effect of the stem cell therapy can last much longer. We were also encouraged by some other happy surprises during the clinical study.
"For example, this therapy appears to reverse chronic kidney failure. It was a surprise for all of my team to observe that the kidney function of a 75-year-old patient improved remarkably."
This patient had suffered from diabetes for years, gradually developing diabetic foot and nephropathy. He can now walk freely after having been confined to bed or a wheelchair for six months, and his quality of life has improved significantly. Moreover, he only needs kidney dialysis one time a week instead of three times. In a follow-up visit he excitedly told us that he was hopeful that in the near future he could be completely rid of diabetes.
A 19-year-old boy, diagnosed as T1DM five years ago, received his first Diabetes Stem Cell Cocktail in December 2009. He said: “I am physically recovered and mentally improved markedly. My blood sugar is very stable, around 5 mmol/L and I even don’t even need insulin injections anymore. This insulin-independent condition is a dream that I always have had and now it comes true.
Diabetes, an increasingly spreading disease, can lead to life-threatening diseases such as blindness, amputation, strokes, or kidney failure in its natural course. Current treatments, including insulin, cannot change this situation.
"We believe that our stem cell therapy will bring promising hope for patients suffering from diabetes and its complications," comments Cindy Hao, CEO of Cellonis. "Personalized diabetes therapies for patients of various conditions will be developed by Cellonis in the near future. We believe what we have restored for patients will not only be their natural insulin production, but also a normal life filled with the activities non-diabetes sufferers can enjoy daily."
Cellonis Biotechnologies (cellonis.com) focuses on R&D and the clinical application of novel personalized stem cell therapies and immunotherapies for patients with diseases including cancer, diabetes and central nervous system disorders.
Contact: Urs J. Lienert, COO-International, Cellonis Biotechnologies Co., Ltd, +86-150-1054-7487, urs.lienert[.]cellonis.com.
Cellonis Biotechnology is a Beijing and Hong Kong-based biotechnology company focused on Research & Development, Clinical Trials and Application of novel cell and stem cell therapies and immunotherapies for providing in their partner hospitals effective, personalized therapies for patients with diseases such as different cancers, diabetes and CNS.